HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global animal testing alternatives

This article was originally published in The Rose Sheet

Executive Summary

The 30-member Organization for Economic Co-operation and Development has officially adopted two ICCVAM-recommended non-animal, ocular toxicity testing methods as Health Effects Test Guidelines, the Interagency Center on the Validation of Alternative Methods reports Sept. 10. Rather than using animals, the bovine corneal opacity and permeability and isolated chicken eye methods now can be used internationally to identify substances that may cause irritation or damage to eyes. OECD's adoption of the strategies was "fastest ever" due largely to ICCVAM's "comprehensive" evaluation and the involvement of validation organizations in Europe and Japan, as encouraged by memorandum of understanding signed earlier this year to promote global harmonization (1"The Rose Sheet" May 4, 2009). U.S. federal agencies accepted the test methods, per ICCVAM's recommendation, in 2008 (2"The Rose Sheet" June 30, 2008). The test guidelines' final versions will be published in late October on the NICEATM/ICCVAM Web site

You may also be interested in...

Adoption Of Alt Testing Methods Should Pick Up Under Cooperation Memo

Agencies from the U.S., EU, Canada and Japan have signed a memorandum of cooperation to accelerate the process by which non-animal testing methods are validated and implemented across the globe

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts